AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22322110
Drug: +6D high
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +6D high water content daily disposable lens
Trial: 22322110
Drug: -6D high
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -6D high water content daily disposable lens
Trial: 19948382
Drug: Buprenorphine-naloxone dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine-naloxone dosing condition (19.7 mg for extreme pain, 15.0 mg for some pain, 12.8 mg for no pain)
Trial: 19948382
Drug: Buprenorphine-naloxone dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine-naloxone dosing condition
Trial: 27930500
Drug: Prior treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior treatment regimen (SSRIs plus sodium valproate)
Trial: 25911899
Drug: rebamipide 300
RxNorm normalized name: Rébamipide
DrugBank: Rebamipide (DB11656)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: rebamipide 300 mg daily for 8 weeks plus rabeprazole 20 mg daily for the first 4 weeks (reb+PPI group)
Trial: 25911899
Drug: rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 20 mg daily for 8 weeks (PPI group)
Trial: 24703195
Drug: Mirabegron 25
RxNorm normalized name: mirabegron 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 25 mg qd
Trial: 24703195
Drug: Mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 50 mg qd
Trial: 25191556
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice (PJ) 500 ml
Trial: 25191556
Drug: Placebo drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drink 500 ml
Trial: 9489264
Drug: Task Force's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task Force's selection of criteria for identifying effective treatments
Trial: 7616875
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of progesterone
Trial: 7616875
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of progesterone
Trial: 6820344
Drug: Verapamil (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (360 mg/die)
Trial: 2139385
Drug: Verapamil (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (240 mg/die)
Trial: 30900392
Drug: Fosaprepitant 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosaprepitant 3.0 mg/kg (up to 150 mg)
Trial: 30900392
Drug: Fosaprepitant 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosaprepitant 1.2 mg/kg (up to 60 mg)
Trial: 30900392
Drug: Fosaprepitant 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosaprepitant 0.4 mg/kg (up to 20 mg)
Trial: 30900392
Drug: Fosaprepitant 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosaprepitant 5.0 mg/kg (up to 150 mg) in subjects under 12 years
Trial: 17233426
Drug: Antidepressants for
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants for major depression
Trial: 90354
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with adriamycin
Trial: 90354
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy without adriamycin
Trial: 31653260
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (attended twice weekly exercise and nutrition classes for 24 weeks)
Trial: 31653260
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (attended didactic healthy lifestyle classes monthly)
Trial: 15289215
Drug: Early invasive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early invasive strategy (medical therapy and coronary angiography at 4 to 48 hours)
Trial: 31085788
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy
Trial: 3310628
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g suspension four times daily for eight weeks)
Trial: 26280662
Drug: Antioxidant-essential oil
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant-essential oil gel applied twice daily after brushing
Trial: 14583134
Drug: 0.5% timolol/2.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol/2.0% MK-507 combination b.i.d.
Trial: 10760103
Drug: SB 290670
RxNorm normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB 290670 (mixed endothelin A and B receptor antagonist)
Trial: 8813984
Drug: Clindamycin (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (1200 mg) via TVA-Bier
Trial: 8813984
Drug: Gentamicin (284
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (284 mg) via TVA-Bier
Trial: 8813984
Drug: Clindamycin (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (1200 mg) via intravenous/intra-arterial injection
Trial: 4015079
Drug: Intranasal HuIFN‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal HuIFN‐alpha 2 (1.25 X 10(6) IU)
Trial: 24182419
Drug: Sumatriptan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (50 mg) plus promethazine (25 mg)
Trial: 24182419
Drug: Sumatriptan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (50 mg) plus placebo
Trial: 26062731
Drug: G-I (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-I (one session treatment of autologous haematopoietic stem cells)
Trial: 26062731
Drug: G-II (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-II (two sessions treatment of autologous haematopoietic stem cells)
Trial: 26062731
Drug: G-I (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-I (one session treatment)
Trial: 26062731
Drug: G-II (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-II (two sessions treatment)
Trial: 26062731
Drug: G-I and
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-I and G-II (both groups)
Trial: 26062731
Drug: G-III (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-III (control group receiving regular liver treatment)
Trial: 23184569
Drug: Spironolactone, 50
RxNorm normalized name: Spironolactone, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone, 50 mg once daily
Trial: 23184569
Drug: Amiloride, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride, 10 mg once daily
Trial: 16769348
Drug: Enteral recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral recombinant human G‐CSF (rhG‐CSF) for 5 days
Trial: 3056473
Drug: Pre-treatment radiologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment radiologic reevaluation
Trial: 28154462
Drug: Yunnan Baiyao
RxNorm normalized name: CAMPHOR (SYNTHETIC) 40.74 mg / MENTHOL 51.84 mg / METHYL SALICYLATE 117.998 mg TOPICAL PATCH [Yunnan Baiyao Pain Relieving]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yunnan Baiyao (1000 mg orally every 12 h for 5 consecutive treatments)
Trial: 26710696
Drug: Sensor augmented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor augmented insulin pump (SAP)
Trial: 26710696
Drug: Double C
RxNorm normalized name: Capsaicin 0.05% Topical application Cream [DOUBLE CAP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double C therapy (continuous subcutaneous insulin infusion and retrospective continuous glucose monitoring)
Trial: 23433188
Drug: rh-APC infusion
RxNorm normalized name: Recombinant human activated protein C (rH-APC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rh-APC infusion (24 mcg kg(‐1) h(‐1) for 96 h)
Trial: 18783459
Drug: Provider Counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provider Counseling + Pharmacotherapy
Trial: 12907900
Drug: Oral protein-bound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral protein-bound polysaccharide K plus 300 mg tegafur/uracil
Trial: 12907900
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg tegafur/uracil alone
Trial: 10539814
Drug: Telmisartan 10
RxNorm normalized name: telmisartan 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 10 mg
Trial: 26474943
Drug: Telmisartan 20
RxNorm normalized name: telmisartan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 20 mg
Trial: 10539814
Drug: Telmisartan (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (all doses)
Trial: 31397288
Drug: CSLT (computerised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSLT (computerised speech and language therapy) plus usual care
Trial: 31397288
Drug: CSLT (computerised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSLT (computerised speech and language therapy)
Trial: 22134175
Drug: Methadone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone with drug abuse counseling
Trial: 19034342
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Mitomycin C instillation
Trial: 10930147
Drug: Genotypic-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotypic-guided therapy (G4)
Trial: 10930147
Drug: Genotypic-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotypic-guided therapy (G3)
Trial: 8452173
Drug: AMX/CP 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMX/CP 500 mg/125 mg three times a day
Trial: 3785797
Drug: Topical 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5-fluorouracil cream (5%, applied biweekly for at least six months)
Trial: 3785797
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic 5-fluorouracil cream
Trial: 28984095
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration analgesia and continuous wound infusion of anesthetics
Trial: 28984095
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration analgesia and continuous wound infusion of saline solution
Trial: 25091593
Drug: Computer-assisted cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted cognitive-behavioral therapy (CBT) - eight sessions led by trained psychologists on a weekly basis
Trial: 19441667
Drug: Escitalopram (n=51)
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram (n=51) with a dose range of 10-20 mg/day
Trial: 12771003
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of N-BNP (or BNP) with LVEF
Trial: 1506124
Drug: Gincosan (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gincosan (60 mg ginkgo biloba + 100 mg ginseng)
Trial: 1506124
Drug: Gincosan (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gincosan (120 mg ginkgo biloba + 200 mg ginseng)
Trial: 26985728
Drug: Control -
RxNorm normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control - printed literature about alcohol and drug use risks
Trial: 20435968
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (local traditional vocational services)
Trial: 30179727
Drug: High-cocoa group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-cocoa group (4 g/d; 220 mg flavanols)
Trial: 30179727
Drug: Middle-cocoa group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle-cocoa group (2 g/d; 110 mg flavanols)
Trial: 16178946
Drug: Lumiracoxib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiracoxib 200 mg
Trial: 17933588
Drug: Lumiracoxib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiracoxib 400 mg
Trial: 12174922
Drug: Leuprorelin acetate
RxNorm normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprorelin acetate 11.25 mg subcutaneous injection every three months for 2 years
Trial: 12174922
Drug: CMF (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF (cyclophosphamide 500 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2, days 1 and 8, q 4 weeks)
Trial: 10441862
Drug: Low-dose prednisolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prednisolone (0.5 mg/kg per day, adjusted to 0.25 mg/kg per day on alternate days)
Trial: 8882570
Drug: Deflazacort (DFC)
DrugBank: Deflazacort (DB11921)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deflazacort (DFC) 0.9 mg/kg/day
Trial: 8882570
Drug: Prednisone (PRED)
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone (PRED) 0.75 mg/kg/day
Trial: 30657179
Drug: Yoga program,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga program, twice a week for 6 weeks
Trial: 27984472
Drug: Weekly spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly spinal stabilization exercises
Trial: 12657858
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg parecoxib sodium
Trial: 12657858
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg parecoxib sodium
Trial: 12069102
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of Q10 (dose-dependent increase)
Trial: 26964166
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection of shuang huanglian injection (1 mL at each point, three times a week for 2 weeks) and fire needling (once a day for 3 times)
Trial: 26964166
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of vitamin C (100 mg, three times a day) and vitamin B2 (20 mg, three times a day) and subcutaneous injection of transfer factor (2 mL, twice a week for 2 weeks)
Trial: 21282560
Drug: Azilsartan medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 40 mg
Trial: 21282560
Drug: Azilsartan medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 80 mg
Trial: 20236700
Drug: Valsartan 320
RxNorm normalized name: valsartan 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 320 mg
Trial: 1758394
Drug: Intravenous Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Cyclophosphamide
Trial: 6210867
Drug: Danazol 200
RxNorm normalized name: danazol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol 200 mg/day
Trial: 30169215
Drug: PPOIT (Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPOIT (Probiotic and Peanut Oral Immunotherapy)
Trial: 22970658
Drug: Flupirtine MR
RxNorm normalized name: FLUPIRTINE
DrugBank: Flupirtine (DB06623)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupirtine MR 400 mg OD
Trial: 22970658
Drug: Tramadol ER
RxNorm normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol ER 200 mg OD
Trial: 9873237
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for infertile couples
Trial: 31173150
Drug: 5-fraction hypofractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fraction hypofractionated stereotactic radiotherapy (HSRT) with a median total dose of 30 Gy (range, 25-35 Gy)
Trial: 25940675
Drug: PF‐05231023 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐05231023 (200 mg)
Trial: 25940675
Drug: PF‐05231023 (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐05231023 (high-dose groups)
Trial: 23836190
Drug: Lapatinib 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 900 mg/m² dose bid for 7-14 days (pre-resection treatment)
Trial: 23836190
Drug: Lapatinib continuously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib continuously at 900 mg/m² dose bid in phase II study
Trial: 19692495
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (100 microg Se/d as l-selenomethionine)
Trial: 7867683
Drug: benazepril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benazepril (10 mg) + amlodipine (5 mg)
Trial: 7867683
Drug: amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine (5 mg) + benazepril (10 mg)
Trial: 17324745
Drug: amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine (5 mg)
Trial: 2092
Drug: Metoprolol 20
RxNorm normalized name: metoprolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 20 mg t.i.d.
Trial: 11598040
Drug: GBS type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBS type III CPS‐tetanus toxoid (III‐TT) conjugate vaccine with alum (12.5 microg dose)
Trial: 11598040
Drug: GBS type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBS type III CPS‐tetanus toxoid (III‐TT) conjugate vaccine without alum (12.5 microg dose)
Trial: 11598040
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of GBS III‐TT conjugate vaccine (12.5 microg dose) for participants with undetectable III CPS‐specific IgG before the first dose
Trial: 24552609
Drug: Touch-screen mode
RxNorm normalized name: benzethonium chloride Medicated Liquid Soap [Lysol Healthy Touch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Touch-screen mode of administration
Trial: 24552609
Drug: Paper-and-pencil mode
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paper-and-pencil mode of administration
Trial: 7649579
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments together
Trial: 180619
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial ligation and portal venous infusion of 5-fluorouracil
Trial: 25368978
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein (HP) infant formula (2.05 g per 100 mL)
Trial: 25368978
Drug: Lower protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower protein (LP) infant formula (1.25 g per 100 mL)
Trial: 16928838
Drug: Tdap vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap vaccine (Sanofi Pasteur - Adacel and GlaxoSmithKline - Boostrix)
Trial: 31418143
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous Molsidomine plus intraventricular sodium nitroprusside (SNP) boluses after TCD-confirmed macrospasm.
Trial: 19695841
Drug: Acute Citalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute Citalopram administration
Trial: 19695841
Drug: Chronic Citalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic Citalopram administration
Trial: 16049380
Drug: PGE2 gel
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 gel
Trial: 12166504
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous corticosteroids
Trial: 10514351
Drug: MCP alone
RxNorm normalized name: mcpa triisopropanolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCP alone delivered via transdermal iontophoresis (IP) at a constant current of 100 microA/cm(2) for 4 hours.
Trial: 1901418
Drug: Fluvoxamine (100‐300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (100‐300 mg/d)
Trial: 1901418
Drug: Maprotiline (50‐150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline (50‐150 mg/d)
Trial: 16637075
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg of clover phytoestrogens daily for 2 weeks
Trial: 10921536
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate supplementation (7.7 pmol, 2200 microg daily for 90 days)
Trial: 1676367
Drug: Fenoldopam (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoldopam (100 mg)
Trial: 29895309
Drug: Standard high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard high protein formula (SHPF) (5 g/100 kcal)